Kazia Therapeutics Ltd Sponsored ADR Stock

$0.39

8.18% yesterday

Nasdaq, Sep 27, 10:00 pm CET

ISIN

US48669G1058

Symbol

KZIA

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Kazia Therapeutics Ltd Sponsored ADR Stock price

$0.39

-3.44 89.71% 5Y

Nasdaq, Closing price Fri, Sep 27 2024

+0.03 8.18%

ISIN

US48669G1058

Symbol

KZIA

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$8.61m
Enterprise Value	$6.43m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
P/B ratio (TTM) P/B ratio	2.67
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-12.90m
Free Cash Flow (TTM) Free Cash Flow	$-8.44m
EPS (TTM) EPS	$-0.44
P/E forward	5.21
P/S forward	86.10
EV/Sales forward	64.30
Short interest	1.05%

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Get Started for Free Today

Kazia Therapeutics Ltd Sponsored ADR Stock Analysis

Unlock Scores for Free

??

1 Analyst has issued a forecast Kazia Therapeutics Ltd Sponsored ADR:

1x Buy

100%

More details on Analyst Estimates Including Price Targets

1 Analyst has issued a forecast Kazia Therapeutics Ltd Sponsored ADR:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Kazia Therapeutics Ltd Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

TTM Annually

Dec '23		+/- %
Revenue	- -	- 100%
- Direct Costs	1.24 1.24	7% 7% -
Gross Profit	-1.24 -1.24	7% 7% -
- Selling and Administrative Expenses	4.64 4.64	43% 43% -
- Research and Development Expense	5.77 5.77	50% 50% -
EBITDA	-12 -12	28% 28% -
- Depreciation and Amortization	1.24 1.24	7% 7% -
EBIT (Operating Income) EBIT	-13 -13	26% 26% -
Net Profit	-10 -10	40% 40% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Kazia Therapeutics Ltd Sponsored ADR Stock News

Neutral

PRNewsWire

●

4 days ago

Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research Symposium

SYDNEY , Sept. 23, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce the presentation of data highlighting promising clinical activity of EVT801 in high grade serous (HGS) Ovarian Cancer at the 15th Biennial Ovarian Cancer Research Symposium, co-presented by American Association of Cancer Research (AACR) and the ...

Neutral

PRNewsWire

●

16 days ago

KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER

SYDNEY , Sept. 12, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce that an agreement has been executed with QIMR Berghofer Medical Research Institute, one of Australia's foremost cancer research centres, to obtain an exclusive license to certain intellectual property rights in relation to combination therapies ...

Positive

InvestorPlace

●

about 2 months ago

Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?

Australian biotech company Kazia Therapeutics (NASDAQ: KZIA ) stock rocked the market after reporting encouraging results from a Phase II/III trial for its glioblastoma brain cancer therapy Paxalisib. The positive results extended the life of patients by over three months compared to the current standard of care.

More Kazia Therapeutics Ltd Sponsored ADR News

Company Profile

Kazia Therapeutics Ltd. engages in the pharmaceutical drug research and development. Its pipeline includes two clinical-stage drug development candidates such as GDC-0084, and Cantrixil. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.

Head office	Australia
CEO	John Friend
Founded	1994
Website	www.kaziatherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now